$319.93
Today
as of Jul 22, 16:52 ET
Last 30 days
Recent Press Releases & News
mixed
▲ 2
● 13
▼ 0
BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5
Is BeOne Medicines AG (ONC) Stock Positioned for Growth After Encouraging ASCO Cancer Data?
BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma
Overview
52-week range
$239
$385
55% of range
Avg surprise (last 3)
+171.8%
Avg reaction (last 2)
+0.7%
50% positive
Latest IV / EM
44%
EM ±10.1% · $320 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 6, 2026 | Mar/2026 | $1.96 | $0.73 | +168.5% | +60.7% | +5.3% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $0.08 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $0.84 | $0.48 | +75.0% | — | — | earnings |
| Wed May 7, 2025 | Mar/2025 | $1.22 | $-0.71 | +271.8% | — | -3.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.09 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.09 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.19 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $0.15 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.28 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 5, 2026 | Jun/2026 | BMO | $1.08 | $0.84 | +28.6% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | $1.35B | — | $1.22B | $1.15B | $952M | — | $831M | $791M |
| Operating income | $250M | — | $163M | $88M | $11M | — | $-120M | $-107M |
| Net income | $227M | — | $125M | $94M | $1M | — | $-121M | $-120M |
| EPS (diluted) | $0.15 | — | $0.08 | $0.06 | — | — | $-0.09 | $-0.09 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $4.79B | $4.55B | $4.04B | $2.76B | $2.52B | $2.63B | $2.70B | $2.59B |
| Inventory | $682M | $608M | $532M | $503M | $495M | $495M | $432M | $443M |
| Total current assets | $6.60B | $6.23B | $5.66B | $4.31B | $3.90B | $3.99B | $3.91B | $3.84B |
| Total assets | $8.55B | $8.19B | $7.63B | $6.30B | $5.84B | $5.92B | $5.83B | $5.71B |
| Long-term debt | $963M | $962M | — | $146M | $160M | $166M | $188M | $185M |
| Total liabilities | $3.79B | $3.83B | $3.50B | $2.53B | $2.34B | $2.59B | $2.39B | $2.35B |
| Total equity | $4.76B | $4.36B | $4.13B | $3.77B | $3.50B | $3.33B | $3.44B | $3.37B |